President Trump has held true on his promise to restore America’s pharmaceutical manufacturing independence, making a bold play that aims to set the country up for years to come.
As the Trump administration looks to bring a reversal to the trend that has shipped virtually all pharmaceutical manufacturing over to China and India throughout the years, NBC News reports that a historic deal was just inked.
“Seeking to secure the nation’s supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation’s first strategic stockpile of key ingredients needed to make medicines,” NBC News says.“The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia.”
Further reports indicate that the company could see a contract extension “for a total of $812 million over 10 years, making it one of the largest awards in” the history of the Biomedical Advanced Research and Development Authority (BARDA).
White House Trade Adviser Peter Navarro, known for his hard stance on China and playing an essential role in the president’s hugely effective trade war with the communist nation, said that the move “will not only help bring our essential medicines home but actually do so in a way that is cost competitive with the sweatshops and pollution havens of the world.”
“This is a historic turning point in America’s efforts to onshore its pharmaceutical production and supply chains,” Navarro added.
HHS Secretary Alex Azar said that the move was “a significant step to rebuild our domestic ability to protect ourselves from health threats.”
CEO and President of Phlow, Dr. Eric Edwards, said in a recent interview “there are not a lot of people wanting to bring back generic medicine manufacturing to the United States that has been lost to India and China over decades. You need someone like the federal government saying this is too important for us not to focus on.”
Phlow Corp’s website describes the company as an America First Company and goes on to say “the United States’ drug supply chain is broken, becoming dangerously dependent upon Foreign Suppliers for our most essential generic medicines.”
The website continues, “Phlow was formed to manufacture low-cost, high quality, essential generic drugs for the United States.”
According to Forbes, Phlow plans to use a manufacturing called “continuous manufacturing” which has proven to be extremely time effective in other industries allowing for quicker response times to any potential shortages that may arise.
The global coronavirus crisis has forced the U.S. along with many other countries around the world to realize that China can not be depended on to reliably manufacture critical supply chain goods.
The revelations that China intentionally covered up the virus, paired with their shipments to other countries containing faulty testing and PPE equipment, have severely damaged China’s manufacturing trustworthiness as the world is forced to open its eyes to their dirty tricks.